Loading...
Topotecan-Vincristine-Doxorubicin in stage 4 high-Risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC: A SIOPEN study.
Amoroso, L Erminio, G Makin, Guy W J Pearson, A Brock, P Valteau-Couanet, D Castel, V Pasquet, M Laureys, G Thomas, C
Amoroso, L
Erminio, G
Makin, Guy W J
Pearson, A
Brock, P
Valteau-Couanet, D
Castel, V
Pasquet, M
Laureys, G
Thomas, C
Citations
Altmetric:
Abstract
Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor. In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol, only patients with metastatic complete response (CR) or partial response (PR) with ≤ three abnormal skeletal areas on iodine 123-metaiodobenzylguanidine ([123I]mIBG) scintigraphy and no bone marrow disease proceed to high dose therapy (HDT). In this study, topotecan-vincristine-doxorubicin (TVD) was evaluated in patients failing to achieve these criteria, with the aim of improving the metastatic response rate.
Description
Date
2018-01
Publisher
Collections
Files
Keywords
Type
Article
Citation
Topotecan-Vincristine-Doxorubicin in stage 4 high-Risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC: A SIOPEN study. 2018, 50 (1):148-155 Cancer Res Treat